search
Back to results

Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST) (InVEST)

Primary Purpose

Clinical High Risk for Psychosis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
InVEST
Sponsored by
Beth Israel Deaconess Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Clinical High Risk for Psychosis focused on measuring clinical high risk for psychosis, psychosis risk syndrome, school functioning, intervention

Eligibility Criteria

12 Years - 22 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion:

  1. age 12-18,
  2. can speak English,
  3. meet broad CHR-P criteria based on the Structured Interview for Psychosis Risk Syndromes (SIPS),
  4. shows at least mild role functioning impairment on the Global Functioning-Role scale (GF:R),
  5. parent is willing to provide permission (and client is willing to assent) for invest coaches to communicate with treatment providers.

Exclusion:

  1. Previously met diagnostic criteria for full psychosis on the Structured Interview for Psychosis Risk Syndromes.
  2. Does not meet inclusion criteria listed above.

Sites / Locations

  • Beth Israel Deaconess Medical Center/ Massachusetts Mental Health CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

InVEST

delayed invest

Arm Description

4 month treatment condition

participants in delayed invest wait four months and are reassessed before taking part in the intervention

Outcomes

Primary Outcome Measures

Feasibility of intervention- recruitment rate
recruitment rates
Feasibility of intervention -Client Satisfaction
Attkisson Client Satisfaction Questionnaire is a seven item scale measuring an individual's personal experience with a service (range 7-28 with higher scores indicating greater level of satisfaction)
Feasibility of intervention- drop out
drop outs

Secondary Outcome Measures

Role functioning
The global functioning role scale is a 10 point scale that rates school or work functioning. The scale ranges from 1-10, with 10 indicating the highest level of functioning.

Full Information

First Posted
October 1, 2021
Last Updated
June 23, 2023
Sponsor
Beth Israel Deaconess Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05114733
Brief Title
Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST)
Acronym
InVEST
Official Title
Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 22, 2022 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to test the efficacy of InVEST (Individualized Vocational and Educational Support and Training) for CHR-P (clinical high risk for psychosis) to address specific role functioning difficulties associated with the CHR-P phase. Our specific goals are: Part 1: Preliminary open trial of InVEST (n = 8) to collect preliminary feasibility and acceptability data by providing the intervention, administering assessments, and collecting focus group and self-report feedback from open trial participants. The open trial phase will help to refine recruitment approaches and to modify the treatment manual as needed. Part 2: Preliminary randomized controlled trial of InVEST vs. Delayed InVEST (DI) to explore preliminary evidence of efficacy of InVEST vs. DI (n = 30). The investigators hope to gain understanding of the feasibility of InVEST and the study's assessment procedures, and to gain a preliminary understanding of the intervention's efficacy for functioning difficulties experienced by young people at CHR-P.
Detailed Description
InVEST is a novel intervention that aims to target three clusters of mechanisms believed to be key in contributing to increasing functional impairment in CHR-P: 1) executive functioning (a cognitive mechanism), 2) increased stress sensitivity (an emotional mechanism), and 3) task initiation difficulties (a behavioral mechanism). Conceptually, these mechanisms are consistent with a CBT conceptualization of role functioning impairment, and the strategies to target each mechanism will be adapted based on existing evidence-based interventions combined with clinical expertise in CHR-P treatment. Finally, our proposed project is based on robust scientific evidence supporting the need for early intervention, targeting functional impairment and related risk factors in individuals at CHR-P. This study will be organized in two parts: Part 1: Manual development and a preliminary open-trial (n = 8) to guide the development and refinement of InVEST through coach experiences and study participant feedback. Participants will complete the intervention and then a post-intervention focus group, providing data on the feasibility of InVEST and to direct the development of the InVEST intervention manual. Part 2: A small, randomized trial comparing InVEST treatment (2 groups, n = 15 each). Participants will be randomized using a delayed treatment design, with half of participants randomized into InVEST and half randomized into a 4-month Delayed InVEST (DI; 4 month wait to start). Primary outcome measures will include CHR-P symptoms; global role functioning; executive functioning; stress sensitivity; task initiation; hopelessness; and suicidality. Overview of Intervention: InVEST for CHR-P The investigators will develop and test the feasibility of InVEST, an educational and vocational functioning intervention designed for youth at CHR-P, ages 12-18. InVEST streamlines CBT-P principles into an intervention model geared towards vocational and educational functioning. InVEST is delivered individually by a "coach" (BA-level clinician) who can meet with youth at the clinic, by phone/ video, or in meetings in the community to provide support for implementing goals. Generally, sessions are once a week for one hour, but can be adjusted depending on client needs. The coach communicates with and serves as a member of a coordinated specialty care team (CSC) for CHR-P and collaborates with the client's individual therapist. The coach begins by identifying the youth's individualized goals and notes any difficulties with executive functioning, task initiation, and/or frustration tolerance. The coach then works with the client and therapist to develop a plan for taking action to accomplish goals and for practicing skills for improving organization, task initiation and managing frustration. Study Procedures Part 1: Development Phase/Open Trial Developing InVEST Manual: The investigators will develop an InVEST manual. Recruitment: During the first year, the investigators will recruit 8 young people meeting broad CHR-P criteria from CEDAR or CHR-P research programs. Meeting broad diagnostic CHR-P criteria will be pre-determined through routine clinic assessments. Releases of Information's will be obtained from all participants upon recruitment to allow sharing of eligibility information for study recruitment. The investigators will slightly stagger these participants into 2 overlapping cohorts, to permit modifications to the protocol. Refine and elaborate InVEST: Refinement will be an iterative process guided by our ongoing experiences in each of the stages. Additionally, the investigators will hold a focus group with the open trial participants, to inform refining the manual, particularly the initial InVEST assessment, which aims to guide how to individualize the intervention to particular client needs. The group will hold a meeting after each stage with all investigators and consultants to review and further refine the manual, including at the end of the development phase. The investigators will make changes to increase InVEST's acceptability, efficacy, efficiency, clarity, and developmental appropriateness. The open trial will inform what protocol accommodations are needed for younger adolescents, changes in content to sessions, whether and how age affects acceptability and feasibility, and whether the intervention needs to be simplified. Assessments: Participants and a parent/ caregiver will complete 2 assessments (screening/baseline and post-treatment). Given our small sample size, treatment feasibility and accessibility are our primary outcomes. Our secondary outcome is role functioning. The investigators will acquire demographic variables and diagnosis from CEDAR records, and the investigators will conduct assessments on the following constructs: CHR-P symptoms; executive functioning; stress sensitivity; task initiation; hopelessness; and suicidality. Focus Group Post-intervention, all open trial participants will be invited to participate in a focus group (n=8) to provide feedback on the intervention, and to inform manual development. Part 2: Pilot Study Phase Aims: The goals of the pilot study are to a) collect data on the feasibility and acceptability of InVEST, b) test and refine the provider training procedures, c) refine and pilot test provider adherence and competency measures, and d) preliminary investigation of InVEST's primary outcome (role functioning) and mechanisms (executive functioning, stress sensitivity, and task initiation). Treatments: After obtaining all relevant consent and assent forms and completing their baseline assessment, participants will be randomized to either InVEST, or to a waitlist, Delayed Invest (DI) condition. Participants in the intervention condition will receive 4 months of InVEST treatment, then complete a post-treatment assessment and then a 4-month follow-up assessment. Delayed Invest participants will participate in their usual treatment without the addition of InVEST for their 4 months. Then, they will complete the 4-month assessment and begin working with an InVEST coach for the next 4 months, followed by a post-InVEST assessment. As a result, all participants will receive 3 assessments (which will allow the study assessment clinician to remain blind to study condition). Additionally, this procedure will allow for some consideration of change during the Delayed InVEST period, and for some consideration of stability after the intervention ends, and will permit all participants to receive the intervention. InVEST will be implemented as a 4-month intervention. Assessments: Participants and a parent/ caregiver will complete 3 assessments (intervention: screening/baseline, post-treatment, 4-month follow-up; waitlist: screening/baseline, pre-treatment, post-treatment). Given our small sample size, treatment feasibility and accessibility are our primary outcomes. Our secondary outcome is role functioning.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clinical High Risk for Psychosis
Keywords
clinical high risk for psychosis, psychosis risk syndrome, school functioning, intervention

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
waitlist control design
Masking
Outcomes Assessor
Masking Description
part 1 is open label design. Next part is RCT waiting list control design. assessors will be unaware of whether the participant was in the waiting list condition or the active condition.
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
InVEST
Arm Type
Experimental
Arm Description
4 month treatment condition
Arm Title
delayed invest
Arm Type
No Intervention
Arm Description
participants in delayed invest wait four months and are reassessed before taking part in the intervention
Intervention Type
Behavioral
Intervention Name(s)
InVEST
Intervention Description
Individualized vocational and educational support and training -- participant works with BA level school/ work coach for four months
Primary Outcome Measure Information:
Title
Feasibility of intervention- recruitment rate
Description
recruitment rates
Time Frame
baseline
Title
Feasibility of intervention -Client Satisfaction
Description
Attkisson Client Satisfaction Questionnaire is a seven item scale measuring an individual's personal experience with a service (range 7-28 with higher scores indicating greater level of satisfaction)
Time Frame
4 months
Title
Feasibility of intervention- drop out
Description
drop outs
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Role functioning
Description
The global functioning role scale is a 10 point scale that rates school or work functioning. The scale ranges from 1-10, with 10 indicating the highest level of functioning.
Time Frame
change from baseline to 4 months and baseline to 8 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion: age 12-22, can speak English, meet broad CHR-P criteria based on the Structured Interview for Psychosis Risk Syndromes (SIPS), shows at least mild role functioning impairment on the Global Functioning-Role scale (GF:R), parent is willing to provide permission (and client is willing to assent) for invest coaches to communicate with treatment providers. Exclusion: Previously met diagnostic criteria for full psychosis on the Structured Interview for Psychosis Risk Syndromes. Does not meet inclusion criteria listed above.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michelle Friedman-Yakoobian
Phone
617-754-1210
Email
mfriedm3@bidmc.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Michelle West
Email
MICHELLE.WEST@CUANSCHUTZ.EDU
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michelle Friedman-Yakoobian, PHD
Organizational Affiliation
Department of Psychiatry at BIDMC - a major teaching hospital of Harvard Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center/ Massachusetts Mental Health Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34309198
Citation
West ML, Parrish EM, Friedman-Yakoobian M. Treatment outcomes for young people at clinical high risk for psychosis: Data from a specialized clinic. Early Interv Psychiatry. 2022 May;16(5):500-508. doi: 10.1111/eip.13187. Epub 2021 Jul 26.
Results Reference
background
PubMed Identifier
34309187
Citation
West ML, Parrish EM, Green J, Howland C, Friedman-Yakoobian M. Individualized vocational and educational support and training for youth at clinical high risk for psychosis. Early Interv Psychiatry. 2022 May;16(5):492-499. doi: 10.1111/eip.13186. Epub 2021 Jul 26.
Results Reference
result

Learn more about this trial

Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST)

We'll reach out to this number within 24 hrs